How to find the symposium location:

Auditorium at Institut Pasteur, rue du Docteur Roux,
Métro line 6 & 12, stop “Pasteur”.



Contact person:

Simone Hess
Tel: +49-30-28460417
FAX: +49-30-28460401
E-mail: hess@mpiib-berlin.mpg.de

This symposium is generously co-sponsored by:

invitrogen
QIAGEN
DHARMACON RNA TECHNOLOGIES
Ambion THE RNA COMPANY An Applied Biosystems Business
BECKMAN COULTER
amaxa biosystems

RIGHT

Symposium

RNAi – Reaching for therapy

· RNAi delivery · miRNAs · in vivo applications

25 October 2006
Institut Pasteur, Paris
9:30 – 17:40





Programme

For registration please visit:
www.ip-right.org

Organising committee: Annick Harel-Bellan, Simone Hess, Elke Müller
Symposium secretariat: Katharina Meyer, Sara Skogsäter, Dominique Wasquel

About RNAi

Only recently it has been found that synthetically produced RNA sequences can be used to "silence" genes in human cells, a phenomenon that relies on the machinery of a naturally occurring gene silencing mechanism and that was lauded as 2002's 'breakthrough of the year' by Science magazine. The technology known as RNA interference (RNAi) gives relatively easy access to analyzing a gene's function and has had great impact on biological research since.

About RIGHT

The RIGHT (RNA Interference Technology as Human Therapeutic Tool) project aims to exploit the vast potential of RNA interference (RNAi) for human therapy. RIGHT involves 22 research institutes and enterprises throughout Europe and is supported by the European Commission's Sixth Framework Programme for Research and Development (FP6). RIGHT combines the strengths of several synergistic competence domains to overcome key technological barriers such as undesired interferon response and insufficient delivery, stability and targeting of RNAi to the appropriate cells. Efficient RNAi reagents are generated both through chemical synthesis of siRNA and vector based gene therapy approaches using shRNA. Strategies are developed for efficient delivery to cells and tissues of diseased organisms. Cell biology and disease models are used to allow addressing their function and effectiveness for the treatment of representative diseases.

Objectives of the symposium

The objective of the RIGHT symposium is to present different findings in research on RNAi in vivo application and therapeutic approaches and to discuss novel strategies to diagnose and successfully treat severe unvanquished diseases.

Symposium Programme

09:30 – 10:00 *Registration*

10:00 – 10:10 **Thomas F. Meyer** (MPI for Infection Biology, Berlin, Germany)
Welcome and Opening remarks

10:10 – 10:50 **Jesper Wengel** (University of Southern Denmark, Odense, Denmark)
and **Jørgen Kjems** (University of Aarhus, Denmark)
Novel strategies in siRNA design and delivery

10:50 – 11:10 **Annick Harel-Bellan** (IAL CNRS, Villejuif, France)
miRNAs and mammalian cell proliferation / differentiation in muscle cells

11:10 – 11:30 **Irene Bozzoni** (Università degli Studi di Roma "La Sapienza", Italy)
miRNAs and mammalian cell proliferation / differentiation in granulocytes

11:30 – 12:00 *Coffee Break*

12:00 – 12:30 **Ralf Kühn** (GSF, Neuherberg, Germany)
Conditional Mutagenesis in the Mouse Brain through RNAi

12:30 – 13:00 **Christina Rondinone** (Hoffman-La Roche, Nutley, USA)
Therapeutic potential of RNAi in metabolic diseases

13:00 – 14:30 *Lunch break*

14:30 – 15:00 **Stephan Kissler** (MIT, Cambridge, USA)
Studying autoimmunity by in vivo RNA interference

15:00 – 15:30 **Cédric Raoul** (Swiss Federal institute of Technology EOFL, Lausanne, Switzerland)
Lentiviral Vector and Adeno-associated Vector-based therapy for Motoneuron disease through RNA interference

15:30 – 16:00 **Patrick Arbuthnot** (University of Witwatersrand, South Africa)
Using expressed sequences that induce RNA interference to counter hepatitis B virus replication in vivo

16:00 – 16:30 *Coffee break*

16:30 – 17:00 **Gerard Wagemaker** (Erasmus University Rotterdam, the Netherlands)
Safety and efficacy issues of retroviral stem cell gene transfer for inherited diseases: introduction to the Consert project

17:00 – 17:30 **Luigi Naldini** (Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy)
Exploiting microRNA regulation to improve the efficacy and safety of gene therapy

17:30 - 17:40 **Thomas F. Meyer** (MPI for Infection Biology, Berlin, Germany)
Closing remarks